Health insurance; fair coverage; epilepsy; termination of coverage; devices; surgeries; effective date.
Summary
HB4294 creates a new health insurance requirement in Oklahoma for individuals diagnosed with epilepsy. It directs all individual and group health insurance policies that cover medical and surgical benefits to provide the same coverage and benefits to enrollees with epilepsy as they would to similarly situated enrollees without epilepsy. The bill also prohibits insurers from terminating or refusing to renew coverage solely because a person has been diagnosed with epilepsy.
In addition, the bill requires health plans to adopt medical policies covering medically necessary neurostimulation devices when prescribed by a licensed physician actively treating the enrollee. The stated purpose is to reduce the risk of sudden unexpected death in epilepsy (SUDEP), and the coverage mandate is tied to medical necessity and physician prescription. The act is scheduled to take effect on November 1, 2026.
Impact
The bill would add a new section to Title 36 of the Oklahoma Statutes, codifying epilepsy-specific insurance protections. It would affect individual and group health insurers by limiting underwriting or renewal actions based solely on an epilepsy diagnosis and by requiring parity in coverage for people with epilepsy. It would also expand mandated benefits by requiring coverage for certain neurostimulation devices, potentially affecting plan design, utilization review, and insurer costs for medical and surgical benefit policies.
Sentiment
The bill appears to have received generally favorable but not unanimous support. It advanced through the House and Senate with clear majorities at each stage, including committee approvals and floor passage, suggesting broad acceptance of the policy goal of protecting people with epilepsy. However, the recorded votes also show meaningful opposition in both chambers, indicating some concern about the insurance mandate and its potential cost or regulatory impact.
Contention
The main points of contention likely centered on the scope of the insurance mandate and the requirement to cover neurostimulation devices. Supporters would view the bill as preventing discrimination against people with epilepsy and improving access to treatment that may reduce SUDEP risk, while opponents may have been concerned about increased premiums, mandated coverage obligations, and limits on insurer discretion. The split votes in the House and Senate suggest that although the bill’s patient-protection goals were broadly accepted, the cost and coverage requirements were not universally supported.